• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com

Paper Details


Harish Thanusubramanian, Amberkar Mohan Babu Vittal Rao, Meena Kumari Kamal Kishore *

Journal Title:World Journal of Pharmaceutical Research

Rheumatoid arthritis is an autoimmune disease which is chronic in nature and the exact etiology is unknown. Genetic and environmental factors disrupt the immune system which causes interaction between the T-cells and antigen presenting cells (APC). Biologic diseasemodifying antirheumatic drugs (DMARDs) are biologic response modifiers that target a particular protein that contributes to rheumatoid arthritis (RA). Biological agents are anti-TNF agents, abatacept, rituximab, tofacitinib citrate, anakinra, tocilizumab and some under trial drugs. Various studies have shown that efficacy of biological DMARD+ conventional synthetic DMARD combination is more effective than only biological DMARD treatment. Various adverse effects are seen with biologics caused due to suppression of the immune system. Biologics are given according to 2013 EULAR (EUROPEAN LEAGUE AGAINST RHEUMATISM). The use of biologics is determined by measuring the disease activity with certain tools like Simplified Disease Activity index (SDAI) and Clinical Disease Activity Index (CDAI).